Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

Wet AMD Clinical Trial

Official title:
Phase II Study Intravitreally Admininstered Ranibizumab in 50 Subjects With AMD Having Received at Least 3 Doses of Intermittent Anti-VEGF Therapy in the Preceding 18 Months

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.

Clinical Trial Description

To determine mean change in visual acuity at 6 and 12 months ;

Study Design

N/A

Related Conditions & MeSH terms

Wet AMD

Clinical Trial Details

NCT number	NCT00804934
Study type	Observational
Source	Retina Institute of Hawaii
Contact
Status	Completed
Phase	Phase 2
Start date	February 2008
Completion date	January 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01016873` - INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD	Phase 2
Withdrawn	`NCT01339949` - Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)	N/A
Recruiting	`NCT04704921` - Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD	Phase 2/Phase 3
Enrolling by invitation	`NCT05210803` - Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
Recruiting	`NCT00403026` - Intravitreal Bevacizumab for Retinal Disorders	N/A
Active, not recruiting	`NCT01310686` - Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy